Cargando…

Insight into 144 patients with ocular vascular events during VEGF antagonist injections

AIM: To record ocular vascular events following injections of vascular endothelium growth factor (VEGF) antagonists. METHODS: Collaborative multicenter case series (48 cases), literature reviews (32 cases), and reports to the FDA (64 cases) of patients that had vascular occlusions during anti-VEGF t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mansour, Ahmad M, Shahin, Maha, Kofoed, Peter K, Parodi, Maurizio B, Shami, Michel, Schwartz, Stephen G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299557/ https://www.ncbi.nlm.nih.gov/pubmed/22419856 http://dx.doi.org/10.2147/OPTH.S29075

Ejemplares similares

Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability
por: Kimoto, Kenichi, et al.
Publicado: (2012)

Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD
por: Moraru, Andreea, et al.
Publicado: (2017)

Fcgbp – A Potential Viral Trap in RV144
por: Schwartz, Jacquelyn L
Publicado: (2014)

Beta and gamma ray studies of /sup 144/Cs, /sup 144/Ba and /sup 144 /La
por: Monnand, E, et al.
Publicado: (1976)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

Vascular toxicities with VEGF inhibitor therapies–focus on hypertension and arterial thrombotic events
por: Touyz, Rhian M., et al.
Publicado: (2018)

Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in patient during pregnancy
por: Kianersi, Farzan, et al.
Publicado: (2021)

Vascular Endothelial Growth Factors and Their Inhibitors in Ocular Neovascular Disorders
por: Homayouni, Mansour
Publicado: (2009)

T144. THE ROLE OF TRANSIENT BETA OSCILLATIONS IN ABERRANT SELECTIVE ATTENTION TO SALIENT EVENTS IN SCHIZOPHRENIA
por: Liddle, Elizabeth, et al.
Publicado: (2018)

Comparison of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Injection: Ranibizumab versus Bevacizumab
por: Hwang, Duck Jin, et al.
Publicado: (2012)

144th LHCC Meeting
Publicado: (2020)

Zerfallsspektroskopie von $^{144}$Xe
por: Müller, Oliver
Publicado: (2013)

Hospital general 144 camas
Publicado: (1987)

144th SPSC Meeting
Publicado: (2022)

Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents for Ocular Vascular Diseases: Clinical Practice Guideline
por: Nikkhah, Homayoun, et al.
Publicado: (2018)

Ocular Vascular Events following COVID-19 Vaccines: A Systematic Review
por: Abu Serhan, Hashem, et al.
Publicado: (2022)

VEGF receptor antagonist Cyclo-VEGI reduces inflammatory reactivity and vascular leakiness and is neuroprotective against acute excitotoxic striatal insult
por: Ryu, Jae K, et al.
Publicado: (2008)

Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review
por: Merani, Rohan, et al.
Publicado: (2015)

Ocular manifestations of idiopathic aplastic anemia: retrospective study and literature review
por: Mansour, Ahmad M, et al.
Publicado: (2014)

Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration
por: Yamashita, Mariko, et al.
Publicado: (2018)

The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy
por: Pożarowska, Dorota, et al.
Publicado: (2016)

A comprehensive insight into the clinicopathologic significance of miR-144-3p in hepatocellular carcinoma
por: Liang, Hai-wei, et al.
Publicado: (2017)

The real Fatou conjecture (AM-144)
por: Graczyk, Jacek, et al.
Publicado: (2014)

Telomerase activity in 144 brain tumours.
por: Sano, T., et al.
Publicado: (1998)

Minutes of the 144th Meeting of the LHCC
por: CERN. Geneva. Large Hadron Collider Experiments Committee, et al.
Publicado: (2020)

Memorandum: holographic part of P-144
por: Kittel, E W
Publicado: (1980)

Health Tract, No. 144: Catching Cold
Publicado: (1863)

Health Tract, No. 144: Household Economy
Publicado: (1863)

Health Tract, No. 144: Catching Cold
Publicado: (1867)

Health Tract, No. 144: Catching Cold
Publicado: (1865)

Inflammatory Complications of Intravitreal Anti-VEGF Injections
por: Cox, Jacob T., et al.
Publicado: (2021)

miR-144 delivered by nasopharyngeal carcinoma-derived EVs stimulates angiogenesis through the FBXW7/HIF-1α/VEGF-A axis
por: Tian, Xiaoyan, et al.
Publicado: (2021)

Single ocular injection of a sustained-release anti-VEGF delivers 6 months pharmacokinetics and efficacy in a primate laser CNV model
por: Adamson, Peter, et al.
Publicado: (2016)

Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey
por: Sheth, Jay U, et al.
Publicado: (2021)

Influence of shell structure on neutron and proton exchange in the reactions $^{144}$Sm on $^{144}$Sm and $^{154}$Sm on $^{154}$Sm
por: Wu, E C, et al.
Publicado: (1981)

Cavatine für Posaune und Klavier, Opus 144 = Cavatine for trombone and piano op. 144
por: Saint-Saëns, Camille, 1835-1921
Publicado: (2012)

Characterization of the transcripts of human cytomegalovirus UL144
por: He, Rong, et al.
Publicado: (2011)

IAU Colloquium 144 : Solar Coronal Structures
por: Rusin, Vojtech, et al.
Publicado: (1994)

144: THE PHYSIOLOGICAL INFORMATION ROLE FOR STROKE PATIENTS
por: Vahdatpour, Tohid, et al.
Publicado: (2017)

Association of Anti-VEGF Injections with Progression of Geographic Atrophy
por: Enslow, Ryan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_e2sl0porir7pfr5503bqmmd9ha